COMMUNIQUÉS West-GlobeNewswire

Medigus Announces Pricing of $10 Million Underwritten Public Offering

19/07/2018 - 12:00

OMER, Israel, July 19, 2018 (GLOBE NEWSWIRE) -- Medigus Ltd. (“Medigus” or the “Company”) (NASDAQ:MDGS) (TASE:MDGS), a medical device company developing minimally invasive endosurgical tools and a leader in direct [...]

PotNetwork Holdings, Inc. Retains Major Law Firms For Guidance on Intellectual Property and FDA Product Registrations

19/07/2018 - 12:00

FT LAUDERDALE, Fla., July 19, 2018 (GLOBE NEWSWIRE) -- via OTC PR WIRE -- PotNetwork Holdings, Inc. (OTC Pink:POTN) announces today that the company has engaged national law firms in Fort Lauderdale, Florida and [...]

HealthLynked Corp. Announces Closing of $2,000,000 Private Placement

19/07/2018 - 11:00

NAPLES, Fla., July 19, 2018 (GLOBE NEWSWIRE) -- HealthLynked Corp. (OTCQB:HLYK), announced today that it has closed a $2,000,000 private placement of common stock and warrants with an institutional investor. [...]

Solon Eiendom ASA :Primary insider notification

19/07/2018 - 08:55

(Oslo, Norway, July 18, 2018) Solon Eiendom ASA Chairman of the Board Simen Thorsen (through his wholly owned company Hortulan AS) has today bought 25.000 shares in Solon Eiendom ASA at a price of NOK 27,911 per share. [...]

Sales Of Olainfarm In Six Months Increase By 5%. The Fastest Growth Recorded In Japan And Belarus

19/07/2018 - 08:25

Olaine, June 18, 2018 Sales Of Olainfarm In Six Months Increase By 5%. The Fastest Growth Recorded In Japan And Belarus Consolidated Results of June and 6 months of 2018 Preliminary consolidated Olainfarm Group sales in [...]

Shire plc : Rule 2.9 Announcement

19/07/2018 - 08:01

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN WHOLE OR IN PART IN, INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OR REGULATIONS OF THAT JURISDICTION. 19 July 2018 Shire [...]

MorphoSys and Galapagos Sign Global License Agreement for MOR106 with Top Pharma Partner

19/07/2018 - 07:16

Exclusive global license agreement with Novartis on MOR106 MOR106, a monoclonal antibody directed against IL-17C, will be developed further in atopic dermatitis (AtD) and potentially other indications Up-front payment [...]

Basilea reports receipt of milestone payment based on first Cresemba® approval in Latin America

19/07/2018 - 07:16

Basel, Switzerland, July 19, 2018 - Basilea Pharmaceutica Ltd. (SIX: BSLN) announced today that it has received a CHF 2 million milestone payment from its partner Grupo Biotoscana S.L. ("GBT"), based on the first [...]

Novartis demonstrates commitment to lead immuno-dermatology by in-licensing IL-17C compound for atopic dermatitis

19/07/2018 - 07:16

Novartis enters an exclusive license agreement with Galapagos and MorphoSys for an investigational biologic compound, MOR106, a novel antibody directed against IL-17C IL-17C is believed to contribute significantly to [...]

Evolus, Inc. Announces Pricing of Public Offering of Common Stock

19/07/2018 - 04:20

IRVINE, Calif., July 18, 2018 (GLOBE NEWSWIRE) -- Evolus, Inc. (Nasdaq:EOLS) (“Evolus”) announced today the pricing of its public offering of 4,000,000 shares of common stock at a public offering price of $20.00 per [...]

Establishment Labs Announces Pricing of Initial Public Offering

19/07/2018 - 03:36

NEW YORK, July 18, 2018 (GLOBE NEWSWIRE) -- Establishment Labs Holdings Inc. (NASDAQ:ESTA), a global medical technology company focused on breast aesthetics and reconstruction technologies, today announced the pricing [...]

Cara Therapeutics Announces Pricing of $85.5 Million Offering of Common Stock

19/07/2018 - 02:53

STAMFORD, Conn., July 18, 2018 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc. (Nasdaq:CARA), a clinical-stage biopharmaceutical company focused on developing and commercializing new chemical entities designed to alleviate [...]

AC Immune Announces Price of USD 11.75 for Offerings and Issuance of up to 10 Million Common Shares

19/07/2018 - 01:17

Lausanne, Switzerland, July 19, 2018 - AC Immune SA (NASDAQ: ACIU), a Swiss-based, clinical-stage biopharmaceutical company focused on neurodegenerative diseases, today announced the price per common share of USD 11.75 [...]

Vigil Health Solutions Announces Normal Course Issuer Bid

19/07/2018 - 01:16

VICTORIA, British Columbia, July 18, 2018 (GLOBE NEWSWIRE) -- Vigil Health Solutions Inc. (“Vigil” or the “Company”) (TSX-VEN:VGL) announced today that the TSX Venture Exchange (the “Exchange”) has accepted a notice of [...]

Emergent BioSolutions to Release Second Quarter 2018 Financial Results and Conduct a Conference Call on August 2, 2018

18/07/2018 - 22:30

GAITHERSBURG, Md., July 18, 2018 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE:EBS) will host a conference call on Thursday, August 2, 2018 at 5:00 pm (Eastern Time) to discuss the financial results for the [...]

LeMaitre Vascular Will Announce Second Quarter 2018 Earnings Results on July 26, 2018

18/07/2018 - 22:15

BURLINGTON, Mass., July 18, 2018 (GLOBE NEWSWIRE) -- LeMaitre Vascular, Inc. (Nasdaq:LMAT) announced today that it will release its second quarter 2018 financial results on Thursday, July 26, 2018, after the market [...]

Resonant Engages LHA for Strategic Investor Relations Services

18/07/2018 - 22:05

GOLETA, Calif., July 18, 2018 (GLOBE NEWSWIRE) -- Resonant Inc. (NASDAQ:RESN), a leader in transforming the way radio frequency, or RF, front-ends are being designed and delivered for wireless devices, today announced [...]

Cancer Genetics Closes $2.625 million Convertible Note Financing

18/07/2018 - 22:05

RUTHERFORD, N.J., July 18, 2018 (GLOBE NEWSWIRE) -- Cancer Genetics, Inc. (Nasdaq:CGIX), a leader in enabling precision medicine for oncology through molecular markers and diagnostics, today announced the closing of a $ [...]

BioPorto submits FDA application for The NGAL Test™

18/07/2018 - 21:04

July 18, 2018 Announcement no. 13 BioPorto A/S (“BioPorto”) announces today that the company has submitted an application to the US Food and Drug Administration, (“FDA”), for regulatory clearance of The NGAL Test™ for [...]